Last reviewed · How we verify
docetaxel and ketoconazole
At a glance
| Generic name | docetaxel and ketoconazole |
|---|---|
| Sponsor | National University Hospital, Singapore |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
- Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer (PHASE2)
- Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer (PHASE2)
- Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer (PHASE3)
- Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel (PHASE2)
- Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer (PHASE2)
- Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- docetaxel and ketoconazole CI brief — competitive landscape report
- docetaxel and ketoconazole updates RSS · CI watch RSS
- National University Hospital, Singapore portfolio CI